Literature DB >> 2208133

Human glioblastoma cells release interleukin 6 in vivo and in vitro.

E Van Meir1, Y Sawamura, A C Diserens, M F Hamou, N de Tribolet.   

Abstract

This study demonstrates interleukin 6 (IL-6) production and release by human glioblastomas. Twenty glioblastoma cell lines were tested for IL-6 bioactivity using an IL-6-dependent cell line (7TD1). All of the lines tested with one exception (LN-229) constitutively released IL-6. A significant induction of IL-6 production and secretion was observed when LN-229 cells were treated with interleukin 1 beta (IL-1 beta) or tumor necrosis factor alpha. Various amounts of IL-6 mRNA were found in five of six cell lines tested. IL-6 mRNA was detected in line LN-229 only when the cells were treated with IL-1 beta or tumor necrosis factor alpha, confirming the bioassay data. Glioblastoma cells also produce IL-6 in vivo. (a) IL-6 activity was detected in 11 of 13 cerebrospinal fluids and five of five tumor cyst fluids. (b) IL-6 mRNA was found in four of four tumors. (c) Immunohistochemical analysis showed IL-6 within the tumor cells in 15 of 20 glioblastoma sections. In conclusion, biologically active IL-6 is released by almost all glioblastomas both in vitro and in vivo. The elevated levels of serum acute phase proteins and immune complexes found in glioblastoma patients may be the result of this secretion.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2208133

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  91 in total

1.  Soluble Fas-ligand (sFasL) in human astrocytoma cyst fluid is cytotoxic to T-cells: another potential means of immune evasion.

Authors:  B Frankel; S L Longo; G W Canute
Journal:  J Neurooncol       Date:  2000-05       Impact factor: 4.130

Review 2.  Studying a complex tumor: potential and pitfalls.

Authors:  Siyuan Zheng; Milan G Chheda; Roel G W Verhaak
Journal:  Cancer J       Date:  2012 Jan-Feb       Impact factor: 3.360

3.  Granulocyte colony-stimulating factor (G-CSF) production by astrocytoma cells and its effect on tumor growth.

Authors:  T Kikuchi; S Nakahara; T Abe
Journal:  J Neurooncol       Date:  1996-01       Impact factor: 4.130

4.  Cellular and tumoural heterogeneity of EGFR gene amplification in human malignant gliomas.

Authors:  K Strommer; M F Hamou; H Diggelmann; N de Tribolet
Journal:  Acta Neurochir (Wien)       Date:  1990       Impact factor: 2.216

Review 5.  Retinoids and the control of growth/death decisions in human neuroblastoma cell lines.

Authors:  G Melino; C J Thiele; R A Knight; M Piacentini
Journal:  J Neurooncol       Date:  1997-01       Impact factor: 4.130

6.  Expression of murine interleukin 7 in a murine glioma cell line results in reduced tumorigenicity in vivo.

Authors:  T Aoki; K Tashiro; S Miyatake; T Kinashi; T Nakano; Y Oda; H Kikuchi; T Honjo
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-01       Impact factor: 11.205

7.  Activation of the NF-κB pathway by the STAT3 inhibitor JSI-124 in human glioblastoma cells.

Authors:  Braden C McFarland; G Kenneth Gray; Susan E Nozell; Suk W Hong; Etty N Benveniste
Journal:  Mol Cancer Res       Date:  2013-02-05       Impact factor: 5.852

8.  Inflammation and Gliomagenesis: Bi-Directional Communication at Early and Late Stages of Tumor Progression.

Authors:  Rui Pedro Galvão; Hui Zong
Journal:  Curr Pathobiol Rep       Date:  2013-03-01

9.  Increased diffusion in the normal appearing white matter of brain tumor patients: is this just tumor infiltration?

Authors:  Andrea Horváth; Gábor Perlaki; Arnold Tóth; Gergely Orsi; Szilvia Nagy; Tamás Dóczi; Zsolt Horváth; Péter Bogner
Journal:  J Neurooncol       Date:  2015-11-27       Impact factor: 4.130

10.  Functional and morphological effects of tumour necrosis factor alpha in an interleukin 6-producing pulmonary large cell carcinoma with sarcomatoid features.

Authors:  T Motoyama; H Watanabe; T Kumanishi; H Usui; H Hashimoto; T Hachisu; I Fukamachi; T Arai; K Takehara
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.